# US 2014/0371212 A1 · Bace inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0371212 A1
- Document ID: US20140371212A1
- Status: Published application
- Kind: A1
- Application number: 14/301,358
- Filed: 2014-06-11
- Published: 2014-12-18
- Earliest claimed: 2013-06-18
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Steven James GREEN; Erik James HEMBRE; Dustin James MERGOTT; Yuan SHI; Brian Morgan WATSON; Leonard Larry WINNEROSKI, JR.
- Web page: https://patentgrep.com/patent/US20140371212A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/04: Antibacterial agents
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound of Formula III: wherein A is: and Z, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound of the formula:
wherein A is:
Z is O or S;
R1 is H, F, Cl, CN, OCH3, OCH2CH2OCH3,
R2 is H, F, Cl, or CH3;
R3 is H, F, Cl, CH3, CF3, C1-C3 alkoxy, OCH2CH2OCH3,
and
R4 is H, F, Cl, or OCH3;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound or salt according to claim 1 in the (cis)-configuration:

### Claim 3 (depends on 2)

The compound or salt according to claim 2 wherein A is:

### Claim 4 (depends on 3)

The compound or salt according to claim 3 wherein A is:

### Claim 5 (depends on 4)

The compound or salt according to claim 4 wherein A is:

### Claim 6

The compound or salt according to 5 wherein A is:

### Claim 7 (depends on 4)

The compound or salt according to claim 4 wherein R3 is OCH3, CH2CF3,

### Claim 8 (depends on 7)

The compound or salt according to claim 7 wherein R3 is OCH3.

### Claim 9 (depends on 1)

The compound or salt according to claim 1 wherein Z is O.

### Claim 10 (depends on 1)

The compound or salt according to claim 1 wherein Z is S.

### Claim 11 (depends on 4)

The compound or salt according to claim 4 wherein Z is O.

### Claim 12 (depends on 4)

The compound or salt according to claim 4 wherein Z is S.

### Claim 13 (depends on 7)

The compound or salt according to claim 7 wherein Z is O.

### Claim 14 (depends on 7)

The compound or salt according to claim 7 wherein Z is S.

### Claim 15 (depends on 1)

The compound or salt according to claim 1 which is N-[3-[(4aR,7aS)-2-amino-4a-fluoro-5,7-dihydro-4H-furo[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-phenyl]-5-cyano-pyridine-2-carboxamide.

### Claim 16 (depends on 15)

The compound according to claim 15 which is N-[3-[(4aR,7aS)-2-amino-4a-fluoro-5,7-dihydro-4H-furo[3,4-d][1,3]oxazin-7a-yl]-4-fluoro-phenyl]-5-cyano-pyridine-2-carboxamide.

### Claim 17 (depends on 1)

A method of treating Alzheimer's disease in a patient, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable salt thereof according to claim 1 with one or more pharmaceutically acceptable carriers, diluents, or excipients.
